771581-15-8

Basic information

• Product Name: 2-AMINOMETHYL-3-CHLOROPYRAZINE
• Synonyms: 2-AMINOMETHYL-3-CHLOROPYRAZINE;RARECHEM AL BW 0872;(3-CHLOROPYRAZIN-2-YL)METHYLAMINE;(3-Chloropyrazin-2-yl)methanamine;C-(3-Chloro-pyrazin-2-yl)-MethylaMine;2-pyrazineMethanaMine, 3-chloro-;(3-Chloropyrazin-2-yl)
• CAS NO: 771581-15-8
• Molecular Formula: C₅H₆ClN₃
• Molecular Weight: 143.57
• Mol File: 771581-15-8.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 233.8 °C at 760 mmHg
• Flash Point: 95.2 °C
• Appearance: /
• Density: 1.331 g/cm³
• Vapor Pressure: 0.0548mmHg at 25°C
• Refractive Index: 1.578
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 5.87±0.29(Predicted)
• CAS DataBase Reference: 2-AMINOMETHYL-3-CHLOROPYRAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINOMETHYL-3-CHLOROPYRAZINE(771581-15-8)
• EPA Substance Registry System: 2-AMINOMETHYL-3-CHLOROPYRAZINE(771581-15-8)

Safety Data

• Hazardous Substances Data: 771581-15-8(Hazardous Substances Data)

Usage

Description

2-Aminomethyl-3-chloropyrazine is an organic compound with the molecular formula C5H5ClN4. It is a heterocyclic compound featuring a pyrazine ring with a chlorine atom at the 3-position and an aminomethyl group at the 2-position. 2-Aminomethyl-3-chloropyrazine is known for its potential applications in the pharmaceutical industry, particularly in the development of novel therapeutic agents.

Uses

Used in Pharmaceutical Industry:
2-Aminomethyl-3-chloropyrazine is used as a key intermediate in the synthesis of 8-Amino-imidazo[1,5-a]pyrazine-based Bruton’s tyrosine kinase (BTK) inhibitors. These inhibitors are being developed for the treatment of rheumatoid arthritis, an autoimmune disease characterized by chronic inflammation and pain in the joints.
2-Aminomethyl-3-chloropyrazine plays a crucial role in the development of BTK inhibitors due to its ability to modulate the activity of Bruton's tyrosine kinase, a protein that plays a significant role in the immune system and is implicated in the pathogenesis of rheumatoid arthritis. By inhibiting BTK, these compounds can potentially reduce the inflammation and pain associated with the disease, offering a new therapeutic option for patients suffering from rheumatoid arthritis.

InChI:InChI=1/C5H6ClN3/c6-5-4(3-7)8-1-2-9-5/h1-2H,3,7H2

Upstream product

• 1289386-07-7 2-(3-chloropyrazinyl)methyl bromide 
• 95-58-9 2-chloro-3-methylpyrazine 
• 55557-52-3 2-chloro-3-cyanopyrazine 
• 89283-32-9 (3-chloropyrazin-2-yl)methanol 
• 867165-55-7 2-((3-chloropyrazin-2-yl)methyl)isoindoline-1,3-dione 

Downstream Products

• 1320266-92-9 8-chloro-1-iodo-3-isopropylimidazo[1,5-a]pyrazine 
• 1320266-94-1 1-iodo-3-isopropylimidazo[1,5-a]pyrazin-8-amine 
• 1320266-90-7 8-chloro-3-isopropylimidazo[1,5-a]pyrazine 
• 1320266-96-3 C₁₀H₁₄ClN₃O 
• 1620675-75-3 (2R,5S)-benzyl 5-(((3-chloropyrazin-2-yl)methyl)carbamoyl)-2-(methoxymethyl)piperidine-1-carboxylate 
• 1418307-18-2 (S)-2-(8-chloroimidazo[1,5-a]pyrazin-3-yl)-1-pyrrolidinecarboxylic acid benzyl ester 
• 1420478-87-0 benzyl (2S)-2-(1-bromo-8-chloro-imidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate 
• 1420478-88-1 benzyl (2S)-2-(8-amino-1-bromo-imidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate 
• 1419221-77-4 benzyl (3R)-3-([(3-chloropyrazin-2-yl)methyl]carbamoyl)piperidine-1-carboxylate 
• 1419221-78-5 benzyl (3R)-3-(8-chloroimidazo[1,5-a]pyrazin-3-yl)piperidine-1-carboxylate 
• 1419221-79-6 benzyl (3R)-3-(1-bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)piperidine-1-carboxylate 
• 1419221-80-9 benzyl (R)-3-(8-amino-1-bromoimidazo[1,5-a]-pyrazin-3-yl)piperidine-1-carboxylate 
• 1418307-23-9 benzyl (2S)-2-([(3-chloropyrazin-2-yl)methyl]carbamoyl)piperidine-1-carboxylate 
• 1419221-81-0 benzyl (3R)-3-(8-amino-1-(4-[(pyridin-2-yl)carbamoyl]phenyl)imidazo[1,5-a]pyrazin-3-yl)piperidine-1-carboxylate 

Relevant articles and documents

Substituted aromatic fused ring derivative, composition containing same and application

The invention provides a substituted aromatic fused ring derivative, a composition containing the compound and application. The substituted aromatic fused ring derivative is a compound shown in a formula (I) or a tautomer, a stereoisomer, a prodrug, a cry

Method for preparing Acalabrutinib, in particular to method for preparing Acalabrutinib

The invention relates to the field of chemical synthesis, in particular to a chemical synthesis method for preparing Acalabrutinib. The synthesis method of the compound 3 is optimized, wherein the cyano compound 2 is reduced to obtain the compound 3 by adopting a method of generating borane in situ under the conditions of indium trichloride and sodium borohydride. The method is simple and convenient to operate, a special reaction container and hydrogen are not needed for reduction, a high-risk material catalyst nickel is prevented from being adopted, and large-scale production is facilitated.In the preparation of the compound 15, water is used as a solvent, equivalent hydrogen peroxide is added to react the compound 13 with the compound 14 to prepare the compound 15, so that the method iseconomic and environment-friendly, the post-treatment is simple and convenient, and the reaction liquid is directly subjected to centrifugal operation; in addition, the yield is high and can reach 90% or above; and the compound 15 is high in purity and does not need to be further purified, so that the technology can satisfy the requirements of industrial production.

Alkynyl (hetero) aromatic ring compound for inhibiting activity of protein tyrosine kinase

The present invention relates to an alkynyl (hetero) aromatic ring compound having protein tyrosine kinase inhibition effect, and a preparation method thereof, a pharmaceutical composition containingthe alkynyl (hetero) aromatic ring compound, and uses of